Sunovion announces acceptance by FDA of NDA for Dasotraline to treat Binge Eating Disorder

Sunovion Pharmaceuticals announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for dasotraline, a novel dopamine and norepinephrine reuptake inhibitor (DNRI), for the treatment of patients with moderate-to-severe binge eating disorder (BED).